Manuel Abal, Virginia Balouz, Rosana Lopez, M Eugenia Giorgi, Carla Marino, Cintia V Cruz, Jaime Altcheh, Carlos A Buscaglia
BACKGROUND: Proper evaluation of therapeutic responses in Chagas disease is hampered by the prolonged persistence of antibodies to Trypanosoma cruzi measured by conventional serological tests and by the lack of sensitivity of parasitological tests. Previous studies indicated that tGPI-mucins, an α-Gal (α-d-Galp(1→3)-β-d-Galp(1→4)-d-GlcNAc)-rich fraction obtained from T. cruzi trypomastigotes surface coat, elicit a strong and protective antibody response in infected individuals, which disappears soon after successful treatment...
January 18, 2024: PLoS Neglected Tropical Diseases